Overview

Mercaptopurine Therapy in Ulcerative Colitis

Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
This project is a double-blind, randomized, placebo-controlled, multicenter trial in the Netherlands. The aim of this study is to investigate the therapeutic efficacy of optimized 6-mercaptopurine (6-MP) in ulcerative colitis patients. Therapeutic drug monitoring (TDM) will be performed in order to optimize treatment outcomes and objective endoscopic endpoints will be used.
Phase:
Phase 3
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Treatments:
6-Mercaptopurine
Mercaptopurine
Mesalamine
Prednisone